Werewolf Therapeutics, Inc. · NASDAQ:HOWL
ANSBERT GADICKE reported a 13.40% stake in Werewolf Therapeutics, Inc. (Schedule 13D/A)
Event Oct 31, 2025 · Filed Nov 4, 2025
ANSBERT GADICKE reported a 13.40% stake in Werewolf Therapeutics, Inc., 6,147,610 shares, with active intent on Oct 31, 2025. Filed Nov 4, 2025 (Schedule 13D/A).
- Stake
- 13.40%
- Shares
- 6,147,610
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| MPM BioVentures 2014, L.P. | 5.80% | 2,666,424 |
| MPM BioVentures 2014 (B), L.P. | 0.40% | 177,846 |
| MPM Asset Management Investors BV2014 LLC | 0.20% | 91,778 |
| UBS Oncology Impact Fund L.P. | 4.80% | 2,204,251 |
| MPM BioVentures 2014 GP LLC | 6.20% | 2,844,270 |
| MPM BioVentures 2014 LLC | 6.40% | 2,936,048 |
| Oncology Impact Fund (Cayman) Management L.P. | 4.80% | 2,204,251 |
| MPM BioImpact LLC | 4.80% | 2,204,251 |
| ANSBERT GADICKE | 13.40% | 6,147,610 |
| LUKE EVNIN | 8.60% | 3,943,359 |
| Todd Foley | 6.40% | 2,936,048 |
| MPM ASSET MANAGEMENT LLC | 0.90% | 422,201 |
| MPM ONCOLOGY INNOVATIONS FUND LP | 1.30% | 585,110 |
| MPM Oncology Innovations Fund GP LLC | 1.30% | 585,110 |
Source
Related
- Werewolf Therapeutics, Inc.
- Ansbert Gadicke
- Werewolf Therapeutics, Inc. shareholders
- Schedule 13D/A · Ansbert Gadicke · May 12, 2026
- Schedule 13D/A · Ansbert Gadicke · May 5, 2026
- Schedule 13D/A · Ansbert Gadicke · Jan 16, 2026
- Schedule 13D/A · Ansbert Gadicke · Dec 29, 2025
- Schedule 13D/A · Ansbert Gadicke · Dec 3, 2025
- Schedule 13G · Moll Peter · Sep 21, 2026
- Form 4 · Luke Evnin · Jul 8, 2026
- Schedule 13D/A · Ra Capital Management, L.P. · Jul 2, 2026
- Form 4 · Luke Evnin · Jun 29, 2026
- Schedule 13D/A · Ra Capital Management, L.P. · Jun 26, 2026